NICE in preliminary guidance rejects Strensiq (asfotase alfa) as a treatment for hypophosphatasia- Alexion Pharma
The National Institute for Health and Care Excellence (NICE) has announced that in draft guidance it cannot recommend Strensiq (asfotase alfa) from Alexion Pharma as a treatment for patients with hypophosphatasia due to the drug's high price of £366,912 ($552,000) per patient per year. NICE does not dispute that Alexion's Strensiq is effective for the handful of patients, estimated at around seven a year in England, diagnosed with paediatric-onset hypophosphatasia. The NICE decision is still at the draft stage and is open to a period of consultation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.